Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BInnopharmax Inc. 〉OralPAS®



Technological development

Request for Collaboration
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical professionals.

The Company has fully devoted to its R&D operations and has established its Research and Development Center dedicated to supporting the Company's lines of businesses and leveraging its scientific expertise to the Company's maximum advantage. INNOPHARMAX also undertakes contract formulation development of pharmaceuticals ranging from immediate release formulations (IR) to alternative dosage designs and controlled release formulations (CR), based on the company's technology platform and advanced equipments.

On the other hand, INNOPHARMAX has established partnerships with Contract Research Organizations (CROs) and continues to seek out new partners various of research and development areas in order to provide a full package for the clients who need a total solution for their product development.
Solid dosage forms
Tablets (immediate-release, controlled-release)
Capsules (hard gelatin and soft gelatin)
Microencapsulation (pelletization)Liquid dosage forms
Emulsions (microemulsions)
Nanoparticle delivery
OralPAS®Technology Platform
OralPAS® is a Self-Microemulsifying Drug Delivery System Technology
Anhydrous system (or microemulsion preconcentrate) can be used in a liquid or solid dosage form
Forms spontanously a very fine transparent/translucent dispersion in contact with GI fluid and water
Advantages of OralPAS®
Increases the solubility and dissolution of the drug
Protects drugs against enzyme degradation 
Enhances drug absorption through structural or fluidity changes in the intestinal membrane
Can be used as a solid dosage form
People who like this also like
  • Clinical & Regulatory ExpertiseClinical & Regulatory Expertise
  • PHN033 (Diabetic Nephropathy treatment)PHN033 (Diabetic Nephropathy treatment)
  • OralPAS®OralPAS®
  • TLC599TLC599
  • Pegylation PlatformPegylation Platform
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
  • PHDC-02PHDC-02
  • PHDC-01PHDC-01
  • TAH9901 ADHD Trandermal PatchTAH9901 ADHD Trandermal Patch
  • TLC178TLC178